Drug intelligence / Profile preview

CDD-2107

Development stage: Preclinical
Lead developer: Centre for Chinese Herbal Medicine Drug Development

Overview

CDD-2107 is a botanical drug candidate developed by the Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University for the treatment of myofibrillar myopathy, specifically BAG3 gene-related myofibrillar myopathy (Bag3opathy). Derived from the traditional Chinese herbal medicine Chaenomelis Fructus, the drug was identified using multi-omics and artificial intelligence screening technologies to clarify its therapeutic targets. It aims to improve muscle strength, mobility, and independence in patients with this rare hereditary neuromuscular disorder. In 2024, it became the first botanical drug from Hong Kong to receive Orphan Drug Designation from the US FDA.

Targets

BAG3 (Bcl2-associated athanogene 3)

Beyond the preview

Go deeper on CDD-2107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDD-2107.

Explore the full profile